Literature DB >> 12672542

Mouse models of Angelman syndrome, a neurodevelopmental disorder, display different brain regional GABA(A) receptor alterations.

S T Sinkkonen1, G E Homanics, E R Korpi.   

Abstract

Angelman syndrome is a severe neurodevelopmental disorder with cognitive impairment and neurological deficits. It results from a maternal deletion of human chromosome 15q11-13 containing two candidate genes E6-P ubiquitin-protein ligase (UBE3A) and GABA(A) receptor beta3 subunit (GABRB3), the latter of which has been also linked to autism. To clarify the potential role of GABA(A) beta3 subunit-containing inhibitory receptors in these disorders, we applied ligand autoradiography on brain sections from mice with inactivated GABRB3 or maternal UBE3A genes. Binding of GABA(A) receptor channel ([(35)S]t-butylbicyclophosphorothionate) and benzodiazepine ([(3)H]Ro 15-4513) site ligands was reduced in selected brain regions of the beta3-deficient mice as compared to controls, while the UBE3A-deficient mice failed to show reduced GABA(A) receptors. The results, suggesting two different pathophysiological mechanisms, are in agreement with positron emission tomography results from Angelman syndrome patients of the corresponding genetic backgrounds.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12672542     DOI: 10.1016/s0304-3940(03)00123-x

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  11 in total

1.  Epigenetic overlap in autism-spectrum neurodevelopmental disorders: MECP2 deficiency causes reduced expression of UBE3A and GABRB3.

Authors:  Rodney C Samaco; Amber Hogart; Janine M LaSalle
Journal:  Hum Mol Genet       Date:  2004-12-22       Impact factor: 6.150

2.  Neuroanatomic and behavioral traits for autistic disorders in age-specific restricted index selection mice.

Authors:  L Meng; L Lu; K M Murphy; C M Yuede; J M Cheverud; J G Csernansky; H Dong
Journal:  Neuroscience       Date:  2011-05-26       Impact factor: 3.590

3.  Evidence for linkage and association of GABRB3 and GABRA5 to panic disorder.

Authors:  Laura M Hodges; Abby J Fyer; Myrna M Weissman; Mark W Logue; Fatemeh Haghighi; Oleg Evgrafov; Allessandro Rotondo; James A Knowles; Steven P Hamilton
Journal:  Neuropsychopharmacology       Date:  2014-05-23       Impact factor: 7.853

4.  Altered GABA(A) receptor subunit expression and pharmacology in human Angelman syndrome cortex.

Authors:  William H Roden; Lindsey D Peugh; Laura A Jansen
Journal:  Neurosci Lett       Date:  2010-08-06       Impact factor: 3.046

5.  Gabrb3 gene deficient mice exhibit impaired social and exploratory behaviors, deficits in non-selective attention and hypoplasia of cerebellar vermal lobules: a potential model of autism spectrum disorder.

Authors:  Timothy M DeLorey; Peyman Sahbaie; Ezzat Hashemi; Gregg E Homanics; J David Clark
Journal:  Behav Brain Res       Date:  2007-09-14       Impact factor: 3.332

6.  Brain regional heterogeneity of pH effects on GABA(A) receptor-associated [35s]TBPS binding.

Authors:  Mikko Uusi-Oukari; Paula Kosonen; Gregg E Homanics; Esa R Korpi
Journal:  Neurochem Res       Date:  2004-04       Impact factor: 3.996

7.  Analysis of imprinting in mice with uniparental duplication of proximal chromosomes 7 and 15 by use of a custom oligonucleotide microarray.

Authors:  Victoria L Buettner; Jeffrey A Longmate; Michael E Barish; Jeffrey R Mann; Judith Singer-Sam
Journal:  Mamm Genome       Date:  2004-03       Impact factor: 2.957

Review 8.  Autism: a "critical period" disorder?

Authors:  Jocelyn J LeBlanc; Michela Fagiolini
Journal:  Neural Plast       Date:  2011-08-03       Impact factor: 3.599

Review 9.  GABAergic signaling as therapeutic target for autism spectrum disorders.

Authors:  Giada Cellot; Enrico Cherubini
Journal:  Front Pediatr       Date:  2014-07-08       Impact factor: 3.418

Review 10.  Clinical and Neurobiological Relevance of Current Animal Models of Autism Spectrum Disorders.

Authors:  Ki Chan Kim; Edson Luck Gonzales; María T Lázaro; Chang Soon Choi; Geon Ho Bahn; Hee Jeong Yoo; Chan Young Shin
Journal:  Biomol Ther (Seoul)       Date:  2016-05-01       Impact factor: 4.634

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.